Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ijantimicag.2006.08.018
DC FieldValue
dc.titleOutpatient parenteral antibiotic therapy in Singapore
dc.contributor.authorFisher, D.A.
dc.contributor.authorTambyah, P.A.
dc.contributor.authorSulaiman, Z.
dc.contributor.authorKurup, A.
dc.contributor.authorLee, W.
dc.contributor.authorKaur, V.
dc.contributor.authorLye, D.
dc.contributor.authorPoon, E.Y.H.
dc.contributor.authorLim, P.L.
dc.date.accessioned2011-09-27T05:14:54Z
dc.date.available2011-09-27T05:14:54Z
dc.date.issued2006
dc.identifier.citationFisher, D.A., Tambyah, P.A., Sulaiman, Z., Kurup, A., Lee, W., Kaur, V., Lye, D., Poon, E.Y.H., Lim, P.L. (2006). Outpatient parenteral antibiotic therapy in Singapore. International Journal of Antimicrobial Agents 28 (6) : 545-550. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijantimicag.2006.08.018
dc.identifier.issn09248579
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26716
dc.description.abstractOutpatient parenteral antibiotic therapy (OPAT) remains in its infancy in Singapore, with the first patients enrolled 4 years ago. Singapore's three largest hospitals, with over 3000 inpatient beds, now have designated and approved OPAT services. This study reviews the demographic, clinical and cost data of all patients enrolled in 2005 to facilitate benchmarking between services in Singapore and abroad and also to identify common needs for further development. In 2005, 225 OPAT enrolments in 208 different patients resulted in 4050 days of OPAT care. Orthopaedic diagnoses constituted 40% of admissions. Vancomycin was the most frequently used antibiotic (34%). The re-admission rate was 8.9%, but complications of OPAT care were only occasionally implicated. An estimated $207 200 was saved by patients despite there being significant financial disincentives to subsidised patients. OPAT is a safe, cost-efficient system that is becoming increasingly accepted in Singapore by patients, clinicians and management. Our three services have evolved independently into very similar practices. There is potential for further innovation, including outreach and carer-delivered dosing. However, major financial disincentives require review. © 2006 Elsevier B.V. and the International Society of Chemotherapy.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ijantimicag.2006.08.018
dc.sourceScopus
dc.subjectAntibiotic
dc.subjectMedisave
dc.subjectOPAT
dc.subjectOutpatient
dc.subjectOutpatient parenteral antibiotic therapy
dc.subjectSingapore
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.ijantimicag.2006.08.018
dc.description.sourcetitleInternational Journal of Antimicrobial Agents
dc.description.volume28
dc.description.issue6
dc.description.page545-550
dc.identifier.isiut000242958000011
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

33
checked on Jul 18, 2019

WEB OF SCIENCETM
Citations

30
checked on Jul 18, 2019

Page view(s)

231
checked on Jul 5, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.